ReviewCNS drugs2007
Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation.
Review in CNS drugs, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The neglected association between schizophrenia and bone fragility: a systematic review and meta-analyses.Translational psychiatry · 2024Pooled it
- Bone Mineral Density in Schizophrenia: An Update of Current Meta-Analysis and Literature Review Under Guideline of PRISMA.Medicine · 2015Pooled it
- Bone mineral density, prolactin, estradiol, testosterone levels and related research in male chronic patients with schizophrenia.BMC psychiatry · 2026Article
- Association of schizophrenia with fracture-related femoral neck displacement: A cross-sectional retrospective study.PCN reports : psychiatry and clinical neurosciences · 2024Article
- A trans-ethnic two-stage polygenetic scoring analysis detects genetic correlation between osteoporosis and schizophrenia.Clinical and translational medicine · 2020Article
- Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.Scientific reports · 2019Article
- Article
- Chronic Psychosocial Stress Impairs Bone Homeostasis: A Study in the Social Isolation Reared Rat.Frontiers in pharmacology · 2016Article
- Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.Endocrinology · 2015Article
- Bone Mineral Density as a Marker of Cumulative Estrogen Exposure in Psychotic Disorder: A 3 Year Follow-Up Study.PloS one · 2015Article
- Osteoporosis and fracture risk in people with schizophrenia.Current opinion in psychiatry · 2012Review
- Article
- Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study.Psychiatry investigation · 2010Article
- Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.BMC musculoskeletal disorders · 2010Article
- Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.CNS drugs · 2009Review
- Secondary effects of antipsychotics: women at greater risk than men.Schizophrenia bulletin · 2009Review
- Affective Disorders, Bone Metabolism, and Osteoporosis.Clinical reviews in bone and mineral metabolism · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis is recognised as a major public health issue leading to bone fractures, pain and disability. Awareness of an elevated risk of osteoporosis in individuals with schizophrenia is increasing. An accelerated decrease in bone mineral density (BMD) in patients with schizophrenia may be disease related or drug induced. A drug-induced decrease in BMD has been attributed mostly to hyperprolactinaemia and its consequences. However, as demonstrated in this review, decreased BMD and osteoporosis are multifactorial processes, and abnormal bone structure and functions are not limited to BMD. Multiple dynamic processes may lead to impairment of bone homeostasis and eventually to bone abnormalities. Many of these processes may be abnormal in treated as well as untreated patients with schizophrenia. Despite many publications, the epidemiology of abnormal bone structure, mineralisation and dynamics in patients with schizophrenia is still not fully determined. Comprehensive studies of bone dynamics in individuals with first-episode schizophrenia, as well as in patients treated with various current medications, are needed in order to characterise the problem(s) and then to develop relevant treatment and prevention strategies.
Indexed as
Identifiers
17630817What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.